Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly worldwide, fueling the coronavirus disease 2019 (COVID-19) global pandemic. Patients infected with the virus display a wide range of symptoms including cough, fever, malaise, myalgias, gastrointestinal symptoms, ageusia, and anosmia; some individuals progress to acute respiratory distress syndrome and death. Severe illness typically occurs approximately 1 week after the onset of symptoms and can rapidly progress from mild symptoms.¹ The risk factors for severe COVID-19 include being male, older age, and having cardiovascular disease, lung disease, hypertension, diabetes, or obesity.^2,3